Dr. Levine is a tenured Professor of Neurology & Emergency Medicine and Vice Chairman of Neurology. He is also an Associate Dean for Clinical Research and Faculty Development. Dr. Levine’s Clinical Research interests are in cerebrovascular disease and stroke. He completed his undergraduate education and Neurology Residency at the University of Michigan, Medical School at the Medical College of Wisconsin, and Fellowship in Cerebrovascular Disease/Stroke at the Henry Ford Health Sciences Center/NIH Designated Center for Stroke Research. He was the Detroit area PI for the NIH-funded NINDS rt-PA Stroke Trial that led to FDA approval of the first treatment for acute ischemic stroke – tissue plasminogen activator (tPA). Dr. Levine’s research has been continuously NIH funded for the past 21 years. He has been active in acute and preventive stroke clinical trials for over 20 years. Current major areas of his research involve (a) proteins (antibodies) in the blood that promote clotting may be a new risk factor for predicting recurrent stroke - antiphospholipid antibodies, (b) refining our understanding of the markers for risk and benefits from t-PA treatment for acute ischemic stroke, (c) pioneering the application of telemedicine (real time video-audio telecommunications) to stroke (“Telestroke”), and (d) Acute stroke clinical trials. Dr. Levine has been training stroke subspecialists (fellows) since 1987. He has served as the Editor-in-Chief of the National Stroke Association’s Stroke-Clinical Updates and serves/served on the Editorial Boards of several peer-reviewed journals, including Neurology, Stroke, and Clinical Neuropharmacology.

Clinical Sites

State University of New York (SUNY Downstate)

Steven R. Levine, M.D, Principal Investigator (Overall)